对AKR1B10和阿尔多减少酶 (AR) 的抑制选择性:从分子动力学模拟和自由能量计算中的洞察力
Ping Lin1,2, Yuzhen Niu1,3
1Weifang University of Science and Technology Weifang 262700 China linping07@mails.ucas.ac.cn niuyzh12@lzu.edu.cn.
RSC advances
|September 8, 2023
概括
在癌症中准过度表达的AKR1B10蛋白质是具有挑战性的,因为它与AR的相似性. 这项研究揭示了设计选择性AKR1B10抑制剂的关键相互作用,重点关注范德瓦尔斯,静电和键.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 计算化学计算化学
背景情况:
- AKR1B10在许多癌症中过度表达,并与化疗耐药性有关,呈现出潜在的抗癌标.
- AKR1B10和雄激素受体 (AR) 之间的结构相似性阻碍了选择性AKR1B10抑制剂的发展.
研究的目的:
- 研究AKR1B10抑制剂选择性的基础分子机制.
- 为设计高度选择性的AKR1B10抑制剂提供一个in silico基础.
主要方法:
- 采用了分子力学与Poisson-Boltzmann和表面积 (MM/PBSA) 的计算.
- 我们分析了抑制剂 (Fidarestat,Zopolrestat,MK184,MK204) 与AKR1B10和AR的结合.
主要成果:
- 范德瓦尔斯和静电相互作用是结合自由能量的主要驱动因素.
- 结合 (Y49,H111) 和pi-pi堆叠 (W112) 对于高抑制活性和复合稳定性至关重要.
- 特定的残留物 (W21,V48,Y49,K78,W80,H111,R298,V302) 有利于抑制剂-AKR1B10复合物的稳定性.
结论:
- 设计选择性AKR1B10抑制剂需要重的部分,如基,以区分AKR1B10和AR之间的结合.
- 了解这些相互作用对于推进向癌症治疗的发展至关重要.
更多相关视频
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
1.2K
13:35Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota
Published on: May 23, 2025
466
相关概念视频
Allosteric Proteins-ATCase
5.8K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.8K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Enzyme Inhibition
78.6K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.6K
Structure-Activity Relationships and Drug Design
764
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
764
